Ketorolac Dosing and Outcomes in Neonates Following Congenital Heart Surgery: A Retrospective Analysis
Amy L. Kiskaddon, Neil A. Goldenberg, Trent Abel, Jamie L. Fierstein, Delia Khayat, James A. Quintessenza, Arabela C. Stock- Critical Care and Intensive Care Medicine
BACKGROUND:
Pain management is essential for postoperative surgery. Given the association of opioids with adverse outcomes, interest in the use of nonopioid analgesics, such as ketorolac, has increased. Published data on use in neonates are limited.
OBJECTIVES:
To describe ketorolac dosing and safety and efficacy outcomes in the first 48 hours postcardiac surgery in neonates.
DESIGN:
We performed a single-center retrospective cohort study of neonates (ages < 28 d) who received ketorolac following cardiac surgery from November 2020 to July 2023 (inclusive). The primary safety outcome was a clinically significant decline in renal function, as defined by the composite of an increase in serum creatinine by greater than or equal to 0.3 mg/dL from baseline within 96 hours of ketorolac initiation and urine output less than or equal to 0.5 mL/kg/hr for 6 hours. The secondary safety outcome was clinically significant bleeding, defined as the composite of major bleeding by the International Society on Thrombosis and Hemostasis pediatric criteria and severe/fatal bleeding by the criteria of Nellis et al (2019). Efficacy was measured by opioid utilization based on a standardized pain score-driven analgesia protocol.
INTERVENTIONS:
Ketorolac was administered at 0.5 mg/kg every 6 hours as per an institutional clinical management algorithm.
MEASUREMENTS AND MAIN RESULTS:
Thirty-nine patients met the eligibility criteria. The median ketorolac dose was 0.5 mg/kg/dose, and median (interquartile range [IQR]) duration of therapy was 48 hours (6–48 hr). No patients experienced a significant decline in renal function, and there were no clinically significant bleeding events. The median (IQR) IV morphine milligram equivalents (MMEs)/kg/d of opioid administration was 0.2 MME/kg/d (0.1–0.25 MME/kg/d) at the time of ketorolac initiation and 0.1 MME/kg/d (0.1–0.2 MME/kg/d) at 48 hours post-ketorolac initiation.
CONCLUSIONS:
If validated prospectively, these findings suggest that a ketorolac regimen of 0.5 mg/kg/dose every 6 hours in neonates postcardiac surgery may be safe with regard to renal function and bleeding risk. Additional randomized studies would be needed to determine efficacy with regard to opioid-sparing capacity.